Purpose: A large prostate has been found to correlate with improved prostate cancer survival in men undergoing radical prostatectomy. In the current study we analyzed the relationship of prostate size and prostate specific antigen (PSA) failure in men undergoing brachytherapy for localized prostate cancer.
Disease related factors, including initial prostate specific antigen (PSA), Gleason score and stage, are significant predictors of biochemical failure in men with prostate cancer treated with brachytherapy. 1 PSA density (PSA/prostate volume) has been advocated as a predictor of biochemical failure because it corrects for the increased PSA associated with a large prostate, 2 although the use of PSA density is controversial. 3 However, a large prostate does not adversely affect cancer control in men undergoing radical retropubic prostatectomy. In 1 study tumors within larger prostates were of lower stage, lower Gleason grade, smaller volume, more often clinically insignificant and not different in the number or distribution of positive surgical margins. During a limited median followup of 20 to 25 months patients with a prostate of 75 gm and more were less likely to have biochemical recurrence. 4 The lower likelihood of biochemical recurrence might be the result of early diagnosis. 4, 5 However, early diagnosis might not account for the increased survival of all patients with cancer who have a large prostate. Indeed, some investigators have postulated that paracrine signals acting to regulate epithelial proliferation in benign prostatic hypertrophy (BPH) have beneficial influences on coexistent cancer. 6 In the current study we analyzed the relationship of prostate size and PSA failure in men undergoing brachytherapy for localized prostate cancer.
METHODS
We studied data on 613 men who underwent 125 I radioactive seed implantation from November 1990 to April 2002. Average patient age Ϯ SD was 65 Ϯ 7.2 years. Average prostate volume ultrasonically measured at seed insertion was 40 Ϯ 15 ml (median 38.6). The smallest prostate was 11.5 ml and the largest one was 125 ml.
Mean followup was 53 Ϯ 24 months. Patient followup included digital rectal examinations and serial PSA measurements, usually every 6 months. In some cases followup data were obtained by review of the medical records or telephone interview with the patient and/or primary physician. Table 1 shows disease stages, initial PSA, Gleason scores and minimal radiation dose covering 90% of prostate volume (D90).
All patients underwent radioactive seed implantation as primary definitive therapy. The initial selection criterion for hormonal therapy was prostate gland size. All patients with prostate gland volume 50 cm 3 or greater on transrectal ultrasonography received hormonal ablation with the intent of gland size reduction. After 1995 adverse features, including PSA 10 ng/ml or greater, Gleason score 7 or greater, or stage T2b or greater were added to the selection criteria. A total of 180 patients (29%) received peri-implantation hormonal ablative therapy in addition to brachytherapy, most often consisting of luteinizing hormone releasing hormone agonist and antiandrogen for 3 months before and 2 to 3 months after the implantation procedure. No patient received external beam radiation therapy as part of initial therapy.
A real-time ultrasound guided technique was used for all implants. Prostate volumetric studies were performed intraoperatively by planimetry with transrectal ultrasound imaging using an ultrasound unit (Bruel and Kjaer, Decatur, Georgia) before seed placement. A modified nomogram was used to provide activities for given volumes to deliver a prescription dose of 160 Gy. One month after implantation patients underwent computerized tomography based dosimetry. Dosimetry was performed using a previously described in-house designed system and/or Pinnacle Systems (ADAC Laboratories, Milpitas, California). The implant dose was defined as the dose delivered to 90% of the prostate volume on dosimetry after implantation. 1 Prostate volume is a risk factor for severity of symptoms and urinary retention. After adjusting for age men with prostate volume greater than 50 ml are 3.5 times more likely to have moderate or severe symptoms and 2.4 times more likely to have a maximum flow rate of less than 10 ml per second than are men with a smaller gland. In addition, men with a prostate of greater than 30 ml have 3 times the incidence of acute urinary retention. 7, 8 We used this information to divide the men in our study into 3 prostate volume groups, namely 1-161 with a small (less than 30 ml), 2-323 with an intermediate (30 to 50 ml) and 3-129 with a large (greater than 50 ml) prostate. We used previously established criteria to estimate the risk of PSA failure by dividing the men into 3 risk groups, namely 1-440 at low risk with PSA 10 ng/ml or less, stage T2a or less, or Gleason 6 or less, 2-133 at medium risk with PSA greater than to 15 ng/ml or less, Gleason 7 or stage T2b and 3-40 at high risk with PSA greater than 15 ng/ml, stage greater than T2b, or Gleason 8 or greater.
In a recent study the 8-year freedom from biochemical failure rate after treatment was 88% in low, 81% in moderate and 65% in high risk cases. 1 Biochemical failure was defined using the American Society for Therapeutic Radiology and Oncology definition, that is 3 consecutive PSA increases. 9 Figure 1 shows cumulative PSA failure vs time in months as a function of prostate size. Men with a large prostate had increased freedom from failure compared to men with a small prostate. Failure time in men with an intermediate size prostate was between that for large and small prostates. The difference in failure rates in the 3 groups was significant (log rank test p ϭ 0.0002). At 10 years 84% of men with a small, 94% with a medium and 98% with a large prostate had not experienced PSA failure. Table 2 lists mean failure-free survival times in the 3 size groups.
RESULTS
PSA failure was associated with the standard risk groups defined based on PSA, Gleason score and disease stage. Men in the low risk group had increased freedom from failure compared to men in the high risk group. Failure time in men in the medium risk group was between that for low and high risk ( fig.  2) . The difference in failure rates in the 3 risk groups was significant (log rank test p Ͻ0.0001). Table 3 shows PSA failure in the risk groups. Table 4 shows cumulative PSA failure-free survival by initial PSA and tumor stage.
We further analyzed our data with Cox regression. Large prostate size significantly correlated with increased time to PSA failure (p ϭ 0.013) and it was independent of the significant effects of Gleason score, PSA, disease stage (ie risk group p Ͻ0.001), D90 (p ϭ 0.008) and hormone treatment, including androgen ablation (p ϭ 0.001). Table 5 lists Cox regression details. DISCUSSION BPH is not a risk factor for prostate cancer. 10 However, BPH and prostate cancer are associated with increased serum PSA. As a result, men with a large prostate are likely to undergo biopsies, after which many asymptomatic prostate cancers are diagnosed. 4 Indeed, PSA testing selects men with a larger prostate for biopsy and there has been a significant increase in the size of prostates removed at radical prostatectomy for early stage cancer since the introduction of PSA testing. 11 As mentioned, paracrine signals acting to regulate epithelial proliferation in BPH might have beneficial influences on coexistent cancer. 6 Our finding that the effect of prostate size is independent of risk group (determined by Gleason score, PSA and disease stage) supports the paracrine signal mechanism.
The relationship of large prostate size to improved survival in prostate cancer has 2 important implications. 1) If a circulating substance, such as a cytokine, might be responsible for improved survival, this substance might be useful for treating prostate cancer. 2) Since we found that prostate size is independent of the standard risk factors (PSA, Gleason score and stage) for predicting outcome, we hypothesize that patients at low risk with a small prostate who are treated with brachytherapy might benefit from hormone treatment and larger radiation doses. These measures are now generally reserved for men in the medium or high risk groups, as defined. 
